RESUMO
Background: Patients diagnosed with acute myeloid leukemia (AML) face a heightened susceptibility to infections, which significantly elevates their risk of mortality and disability. The intensity of the chemotherapy treatment and its specific focus on inhibiting myeloid cell divisions render patients especially vulnerable, particularly during the early stages of chemotherapy. This vulnerability is compounded by the occurrence of repeated episodes of prolonged neutropenia, leaving patients highly susceptible to infections. The compromised immune systems of these individuals make them more susceptible to infections, which adversely affect their physical health and overall well-being. Consequently, our study aimed to investigate the range of infections experienced by patients with newly diagnosed AML undergoing different induction chemotherapy. Methods: This was a comparative retrospective study, conducted at a tertiary hospital providing comprehensive cancer care in North India. All newly diagnosed patients with AML, who received induction chemotherapy from January 1, 2012 to November 1, 2022, were identified from the hospital database and included in this study. Results: Four hundred and twenty AML patients treated with either high-intensity or low-intensity induction chemotherapy was observed in this study. It was found that patients who received high-intensity treatment had a higher rate of clinically and microbiologically documented infections, fever without a known cause, and more cases of febrile neutropenia than those who got low-intensity treatment. These differences between the two groups were particularly evident on day 14 (p = 0.0002) and persisted through day 28 (p = 0.005). Conclusions: These findings underscore the effectiveness and downside of high-intensity induction chemotherapy regimens, as evidenced by the higher incidence of infections observed. Further investigation through prospective clinical studies is warranted to better evaluate and validate the efficacy of this approach.
RESUMO
The available information on the abundance of restorative plants on earth is incomplete, and the data regarding botanicals from various countries differ significantly. The substantial development of the worldwide natural botanical market is attributable to the expanding revenue of global drug companies trading herbal medicines. This essential type of traditional medical care is depended on by approx. 72-80% of individuals. Even though numerous restorative plants are readily used, they have never been subject to the same strict quality guidelines as conventional drugs. Nonetheless, it is vital to have specific organic, phytochemical, and molecular tools and methods for identifying restorative plant species so that traditional and novel plant products can be safely used in modern medicine. Molecular biotechnology approaches provide a reliable and accurate way to identify botanicals and can be used to ensure the safety and efficacy of plant-based products. This review explores various molecular biotechnology approaches and methods for identifying botanicals.